<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="glofitamab-tp53-rrdlbcl-zhao">
    <meta name="study:title" content="Glofitamab Chemo-Free Regimens in TP53-mutated R/R DLBCL (Real-World)">
    <meta name="study:fileName" content="GLOFITAMAB-TP53-RRDLBCL-ZHAO.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="3L+">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Glofitamab,Bispecific antibodies,Acalabrutinib,Zanubrutinib,Obutinib,BTK inhibitors,Sintilimab,PD-1 inhibitor,Lenalidomide,Immunomodulatory drugs,Polatuzumab Vedotin,ADC">

    <title>Glofitamab Chemo-Free Regimens in TP53-mutated R/R DLBCL (Zhao PB3271) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <style>
        :root {
            --sobi-dark-blue: #0A2F5C;
            --sobi-orange: #F37021; 
            --sobi-teal: #009B9E;   
            --sobi-yellow: #FFC107; 
            --sobi-light-gray-bg: #F8F9FA;
            --sobi-white: #FFFFFF;
            --sobi-dark-text: #212529;
            --sobi-medium-gray-text: #6c757d; 
            --sobi-light-teal-bg: #E0F2F7;
            --sobi-light-orange-bg: #FFF0E5;
            --sobi-card-border: #DEE2E6;
        }
        body { font-family: 'Inter', sans-serif; background-color: var(--sobi-light-gray-bg); color: var(--sobi-dark-text); font-size: 16px; }
        .slide-container { max-width: 1200px; margin: 20px auto; padding: 25px; background-color: var(--sobi-white); border-radius: 12px; box-shadow: 0 10px 30px rgba(0, 0, 0, 0.08); border: 1px solid var(--sobi-card-border); }
        .visual-abstract-container { background-color: var(--sobi-white); padding: 1.5rem; border-radius: 0.75rem; box-shadow: 0 6px 12px rgba(0,0,0,0.07); margin-bottom: 2rem; border: 2px solid var(--sobi-teal); }
        .visual-abstract-title { font-size: 1.375rem; font-weight: 700; color: var(--sobi-dark-blue); margin-bottom: 1.5rem; text-align: center; border-bottom: 2px solid var(--sobi-orange); padding-bottom: 0.75rem; }
        .visual-abstract-grid { display: grid; gap: 1.5rem; }
        @media (min-width: 768px) { .visual-abstract-grid { grid-template-columns: repeat(2, minmax(0, 1fr)); } }
        @media (min-width: 1024px) { .visual-abstract-grid { grid-template-columns: repeat(4, minmax(0, 1fr)); } }
        .visual-abstract-item { background-color: var(--sobi-light-gray-bg); padding: 1.25rem; border-radius: 0.5rem; border: 1px solid var(--sobi-card-border); display: flex; flex-direction: column; align-items: center; text-align: center; transition: transform 0.2s ease-in-out, box-shadow 0.2s ease-in-out; }
        .visual-abstract-item:hover { transform: translateY(-3px); box-shadow: 0 8px 16px rgba(0,0,0,0.1); }
        .visual-abstract-item svg { width: 3rem; height: 3rem; margin-bottom: 1rem; }
        .visual-abstract-item h4 { font-size: 1rem; font-weight: 600; color: var(--sobi-dark-blue); margin-bottom: 0.5rem; }
        .visual-abstract-item p { font-size: 0.875rem; color: var(--sobi-dark-text); line-height: 1.5; }
        .visual-abstract-item .highlight-value { font-size: 1.5rem; font-weight: 700; color: var(--sobi-orange); display: block; margin-top: 0.5rem; }
        .header-title { color: var(--sobi-dark-blue); border-bottom: 3px solid var(--sobi-orange); padding-bottom: 12px; margin-bottom: 25px; font-size: 2.25rem; }
        .sub-header { color: var(--sobi-dark-text); font-size: 1.20rem; }
        .meta-info { color: var(--sobi-medium-gray-text); font-size: 0.875rem; }
        .section-title { color: var(--sobi-dark-blue); font-weight: 700; margin-top: 25px; margin-bottom: 15px; font-size: 1.4rem; border-left: 5px solid var(--sobi-teal); padding-left: 10px; }
        .sub-section-title { font-size: 1.1rem; font-weight: 600; color: var(--sobi-dark-blue); margin-top: 15px; margin-bottom: 10px; }
        .card { background-color: var(--sobi-white); border: 1px solid var(--sobi-card-border); border-radius: 8px; padding: 20px; margin-bottom: 20px; box-shadow: 0 4px 12px rgba(0,0,0,0.05); }
        .table-container { overflow-x: auto; margin-top: 10px; }
        table { width: 100%; border-collapse: collapse; }
        th, td { border: 1px solid var(--sobi-card-border); padding: 10px; text-align: left; font-size: 0.875rem; vertical-align: top; }
        th { background-color: var(--sobi-light-teal-bg); color: var(--sobi-dark-blue); font-weight: 600; }
        .highlight { color: var(--sobi-orange); font-weight: 600; }
        .footer-info { font-size: 0.85rem; color: var(--sobi-medium-gray-text); margin-top: 35px; text-align: center; border-top: 1px solid var(--sobi-card-border); padding-top: 20px; }
        .chart-container { display: flex; justify-content: center; align-items: center; flex-direction: column; min-height: 300px; padding: 10px; background-color: #fdfdfd; border-radius: 6px; margin-top: 10px; }
        .axis-text { font-size: 0.8rem; fill: var(--sobi-medium-gray-text); }
        .chart-label { font-size: 0.85rem; font-weight: 500; }
        .legend { display: flex; justify-content: center; flex-wrap: wrap; margin-top: 15px; }
        .legend-item { display: flex; align-items: center; margin-right: 15px; margin-bottom: 5px; font-size: 0.8rem; color: var(--sobi-dark-text); }
        .legend-item:last-child { margin-right: 0; }
        .legend-color-box { width: 12px; height: 12px; margin-right: 6px; border-radius: 2px; flex-shrink: 0; }
        .infographic-item { display: flex; flex-direction: column; align-items: center; text-align: center; padding: 15px; border-radius: 8px; margin-bottom:10px; }
        .infographic-item.orange-theme { background-color: var(--sobi-light-orange-bg); }
        .infographic-item.teal-theme { background-color: var(--sobi-light-teal-bg); }
        .infographic-icon { font-size: 2.8rem; margin-bottom: 10px; }
        .icon-orange { color: var(--sobi-orange); }
        .icon-teal { color: var(--sobi-teal); }
        .infographic-value { font-size: 1.75rem; font-weight: 700; color: var(--sobi-dark-blue); }
        .infographic-label { font-size: 0.9rem; color: var(--sobi-dark-text); }
        .list-disc li, .list-circle li { margin-bottom: 5px; }
        .safety-table td ul { list-style-position: inside; padding-left: 0; }
        .safety-table td ul li { margin-bottom: 2px; }
        .abbreviations-list p, .reference-section p { font-size: 0.875rem; line-height: 1.6; color: var(--sobi-dark-text); }
        .footnote-text { font-size: 0.8rem; color: var(--sobi-medium-gray-text); margin-top: 10px; line-height: 1.4; }
        .footnote-text p { margin-bottom: 5px; }
        .study-design-schema { margin-top: 20px; padding: 15px; background-color: var(--sobi-light-gray-bg); border: 1px solid var(--sobi-card-border); border-radius: 6px; font-size: 0.85rem; }
        .schema-title { font-weight: 600; color: var(--sobi-dark-blue); margin-bottom: 15px; text-align: center; }
        .schema-step { background-color: var(--sobi-light-teal-bg); color: var(--sobi-dark-blue); border: 1px solid var(--sobi-teal); padding: 8px 10px; border-radius: 4px; text-align: center; margin-bottom: 8px; }
        .schema-step strong { font-weight: 600; display: block; margin-bottom: 3px; }
        .schema-step span, .schema-step div { font-size: 0.8rem; }
        .schema-arrow-down { text-align: center; font-size: 1.2rem; color: var(--sobi-dark-blue); margin: -2px 0; }
        .schema-assessment-points { display: flex; justify-content: space-around; flex-wrap: wrap; gap: 5px; margin-top: 5px; padding: 8px 0; border-top: 1px dashed var(--sobi-card-border); }
        .schema-assessment-points span { font-size: 0.75rem; color: var(--sobi-medium-gray-text); background-color: var(--sobi-light-orange-bg); padding: 3px 6px; border-radius: 3px; border: 1px solid var(--sobi-orange); }
    </style>
</head>
<body>
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: Glofitamab Chemo-Free Regimens in TP53-mutated R/R DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)">
                        <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=20)</h4>
                    <p>R/R DLBCL Pts with TP53 mutations. Aim: Efficacy & safety of chemo-free Glofitamab combos.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 64 64" fill="var(--sobi-teal)">
                        <path d="M32 60 V40 M20 40 L32 40 L44 40 M20 40 L12 28 L4 20 M44 40 L52 28 L60 20 M12 28 L16 24 M52 28 L48 24" stroke="var(--sobi-teal)" stroke-width="5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
                        <circle cx="4" cy="20" r="3" fill="var(--sobi-orange)"/><circle cx="60" cy="20" r="3" fill="var(--sobi-yellow)"/>
                    </svg>
                    <h4>Intervention</h4>
                    <p>Glofitamab + (BTKi / Sintilimab / Lenalidomide / Polatuzumab Vedotin). Real-world data.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)">
                        <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (N=15 eval.)</h4>
                    <p>ORR: <span class="highlight-value">66.7%</span>CRR: <span class="highlight-value">40.0%</span> (at end of 6th cycle)</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)">
                        <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Generally mild AEs (G1/2 CRS, tumor flare). High efficacy & good tolerability in this high-risk group.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="text-3xl font-bold header-title">CHEMO-FREE REGIMENS CONTAINING GLOFITAMAB ARE SIGNIFICANTLY BENEFICIAL FOR R/R DLBCL PATIENTS WITH TP53 GENE MUTATIONS</h1>
            <p class="text-xl sub-header">Real-World Data from Multi-Centers in China</p>
            <p class="text-sm meta-info mt-2">Xia Zhao, et al. | EHA Library PB3271 | Abstract Release: 05/14/25 | Presentation: 06/12/2025</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="card">
                    <h2 class="section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>TP53 gene mutations are an independent risk factor for poor OS in DLBCL, even with 1L R-CHOP or Pola-R-CHP.</li>
                        <li>Relapse/refractory episodes are common in these patients.</li>
                        <li>No standard regimen exists for R/R DLBCL patients with TP53 gene mutations.</li>
                    </ul>
                </div>

                <div class="card">
                    <h2 class="section-title">Study Aims</h2>
                    <p class="text-sm mb-1">To investigate the clinical efficacy and adverse events of chemo-free regimens containing glofitamab for patients with R/R DLBCL with TP53 gene mutations.</p>
                </div>

                <div class="card">
                    <h2 class="section-title">Methods & Study Design</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Retrospective, multi-center study (3 hospitals in China).</li>
                        <li>Enrollment period: April 2024 - February 2025.</li>
                        <li>Pts: R/R DLBCL with TP53 gene mutations (exons 5-8 detected by NGS).</li>
                        <li>Response assessment: PET-CT by local investigators.</li>
                    </ul>
                    <div class="study-design-schema">
                        <h3 class="schema-title">Treatment Approach Overview (Real-World Data)</h3>
                        <div class="schema-step">
                            <strong>R/R DLBCL Patients with TP53 Mutations (N=20)</strong>
                            <span>Median 4 prior chemo lines; Stage III/IV</span>
                        </div>
                        <div class="schema-arrow-down">â–¼</div>
                        <div class="schema-step">
                            <strong>Chemo-Free Regimens Containing Glofitamab</strong>
                            <div>Glofitamab combined with one of:</div>
                            <ul class="list-disc list-inside text-xs text-left mx-auto mt-1 w-max">
                                <li>BTK inhibitors (Acalabrutinib, Zanubrutinib, or Obutinib)</li>
                                <li>Sintilimab (PD-1 inhibitor)</li>
                                <li>Lenalidomide</li>
                                <li>Polatuzumab vedotin</li>
                            </ul>
                            <span class="text-xs mt-1">(Median 6 cycles of Glofitamab)</span>
                        </div>
                        <div class="schema-arrow-down">â–¼</div>
                        <div class="schema-assessment-points">
                           <span>Safety Assessment (AEs)</span>
                           <span>Efficacy Assessment (ORR, CRR via PET-CT)</span>
                        </div>
                    </div>
                </div>

                 <div class="card">
                    <h2 class="section-title">Patient Characteristics (N=20)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years (range)</td><td>66 (29-79)</td></tr>
                                <tr><td>Male : Female Ratio</td><td>3:1</td></tr>
                                <tr><td>Median Prior Chemotherapy Lines</td><td>4</td></tr>
                                <tr><td>Ann Arbor Stage III/IV, n (%)</td><td>20 (100%)</td></tr>
                                <tr><td>IPI Score â‰¥3, n (%)</td><td>13 (65.0%)</td></tr>
                                <tr><td>â‰¥2 Extranodal Lesions, n (%)</td><td>16 (80.0%)</td></tr>
                                <tr><td>Non-GCB (Hans), n (%)</td><td>17 (85.0%)</td></tr>
                                <tr><td>Median Ki-67, % (range)</td><td>90% (70-90%)</td></tr>
                                <tr><td>Double-Expressor Lymphoma, n (%)</td><td>11 (55.0%)</td></tr>
                                <tr><td>Common TP53 Mutation Position</td><td>Exon 5 and 7</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>

            <div>
                <div class="card">
                    <h2 class="section-title">Treatment Details (N=20)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median number of glofitamab treatment cycles: 6 (range 3-12).</li>
                        <li><strong>Glofitamab Combinations Received:</strong>
                            <ul class="list-circle list-inside ml-4 mt-1">
                                <li>+ BTK inhibitors (acalabrutinib, zanubrutinib, or obutinib): 10 pts</li>
                                <li>+ Sintilimab: 2 pts</li>
                                <li>+ Lenalidomide: 6 pts</li>
                                <li>+ Polatuzumab vedotin: 2 pts</li>
                            </ul>
                        </li>
                    </ul>
                </div>

                <div class="card">
                    <h2 class="section-title">Efficacy Results (N=15 Evaluable Pts*)</h2>
                     <p class="text-xs meta-info mb-2">*Patients who completed at least 6 cycles of glofitamab.</p>
                    <div class="grid grid-cols-1 sm:grid-cols-2 gap-4 mb-4">
                        <div class="infographic-item orange-theme">
                            <div class="infographic-icon icon-orange">ðŸ“Š</div>
                            <div class="infographic-value">66.7%</div>
                            <div class="infographic-label">Overall Response Rate (ORR)</div>
                        </div>
                        <div class="infographic-item teal-theme">
                            <div class="infographic-icon icon-teal">ðŸŽ¯</div>
                            <div class="infographic-value">40.0%</div>
                            <div class="infographic-label">Complete Response Rate (CRR)</div>
                        </div>
                    </div>
                    
                    <div class="chart-container mb-6">
                        <svg id="glofitamabTp53ResponseChart" width="350" height="300"></svg>
                        <div id="glofitamabTp53ResponseLegend" class="legend"></div>
                    </div>
                     <p class="text-sm text-center">Response assessed at the end of the sixth cycle.</p>
                </div>
                
                <div class="card">
                    <h2 class="section-title">Safety Summary</h2>
                    <p class="text-sm">Adverse events were generally mild.</p>
                    <p class="text-sm mt-2"><strong>Most Common Adverse Events:</strong></p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mt-1">
                        <li>Grade 1 or 2 Cytokine Release Syndrome (CRS)</li>
                        <li>Grade 1 or 2 Tumor Flare Reaction</li>
                    </ul>
                    <p class="text-xs meta-info mt-2">(Specific percentages for common AEs not provided in abstract text for N=20).</p>
                </div>
            </div>
        </div>

        <div class="card mt-6">
            <h2 class="section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Chemo-free regimens combined with glofitamab displayed <strong class="highlight">high efficacy</strong> and <strong class="highlight">good tolerability</strong> in heavily pretreated R/R DLBCL patients with TP53 gene mutations.</li>
            </ul>
        </div>

        <div class="card mt-6 abbreviations-list">
            <h2 class="section-title">Abbreviations</h2>
            <p>
                AE, Adverse Event; ADC, Antibody-Drug Conjugate; bABs, Bispecific Antibodies; BTKi, Bruton's Tyrosine Kinase inhibitor; CR, Complete Remission; CRR, Complete Response Rate; CRS, Cytokine Release Syndrome; DLBCL, Diffuse Large B-Cell Lymphoma; EOT, End of Treatment; GCB, Germinal Center B-cell like; Glo, Glofitamab; IPI, International Prognostic Index; IV, Intravenous; LBCL, Large B-Cell Lymphoma; NHL, Non-Hodgkin Lymphoma; NGS, Next-Generation Sequencing; ORR, Overall Response Rate; OS, Overall Survival; PD, Progressive Disease; PD-1, Programmed Death-1; PET-CT, Positron Emission Tomography-Computed Tomography; PFS, Progression-Free Survival; Pola, Polatuzumab vedotin; PR, Partial Remission; Pts, Patients; R, Rituximab; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; R/R, Relapsed/Refractory; SD, Stable Disease.
            </p>
        </div>

        <div class="card mt-6 reference-section">
            <h2 class="section-title">Reference</h2>
            <p>
                Zhao X, Liu Z, Xu J, et al. CHEMO-FREE REGIMENS CONTAINING GLOFITAMAB ARE SIGNIFICANTLY BENEFICIAL FOR RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH TP53 GENE MUTATIONS: REAL-WORLD DATA FROM MULTI-CENTERS IN CHINA. Abstract #PB3271 presented at European Haematology Association (EHA) June 12â€“15, 2025, Milan, Italy.
            </p>
        </div>


        <div class="footer-info">
            <p>EHA Library PB3271 | Presentation Date: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script>
        function drawStackedBarChart(containerId, legendContainerId, chartData, chartTitle) {
            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 350;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = chartWrapper.getBoundingClientRect().width * 0.8; 
            }
            containerWidth = Math.max(containerWidth, 250);

            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");

            const margin = { top: 40, right: 20, bottom: 50, left: 60 }; 
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);

            const categories = ["Response"]; 
            const stack = d3.stack().keys(chartData.keys);
            const stackedData = stack([chartData.values]);

            const xScale = d3.scaleBand()
                .domain(categories)
                .range([0, chartWidth])
                .padding(0.7); 

            const yScale = d3.scaleLinear()
                .domain([0, 100]) 
                .range([chartHeight, 0]);

            g.append("g")
                .attr("transform", `translate(0,${chartHeight})`)
                .call(d3.axisBottom(xScale).tickValues([])) 
                .select(".domain").remove(); 

            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");
            
            g.append("g")			
                .attr("class", "grid")
                .call(d3.axisLeft(yScale)
                    .ticks(5)
                    .tickSize(-chartWidth)
                    .tickFormat("")
                )
                .selectAll("line")
                .style("stroke", "#e0e0e0")
                .style("stroke-opacity", "0.7");

            const color = d3.scaleOrdinal()
                .domain(chartData.keys)
                .range(chartData.colors);

            g.selectAll(".serie")
                .data(stackedData)
                .enter().append("g")
                  .attr("class", "serie")
                .selectAll("rect")
                .data(d => d) 
                .enter().append("rect")
                    .attr("x", d => xScale(categories[0]))
                    .attr("y", d => yScale(d[1]))
                    .attr("height", d => yScale(d[0]) - yScale(d[1]))
                    .attr("width", xScale.bandwidth())
                    .attr("fill", (d, i, nodes) => { 
                        const seriesKey = d3.select(nodes[i].parentNode).datum().key;
                        return color(seriesKey);
                    })
                    .attr("rx", 3).attr("ry", 3);
            
            stackedData.forEach((series) => {
                series.forEach((d) => { 
                    const y0 = d[0];
                    const y1 = d[1];
                    const percentage = y1 - y0;
                    if (percentage > 4) { 
                        g.append("text")
                            .attr("class", "chart-label")
                            .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                            .attr("y", yScale(y0 + percentage / 2) + 4) 
                            .attr("text-anchor", "middle")
                            .style("fill", (series.key === "CR" || series.key === "Other (SD/PD/NR)") ? "white" : "var(--sobi-dark-blue)") 
                            .style("font-size", "10px")
                            .text(`${percentage.toFixed(1)}%`);
                    }
                });
            });

            if (chartData.orr) {
                 g.append("text")
                    .attr("class", "chart-label")
                    .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                    .attr("y", yScale(chartData.orr) - 12) 
                    .attr("text-anchor", "middle")
                    .style("font-weight", "600")
                    .style("fill", "var(--sobi-dark-blue)")
                    .text(`ORR: ${chartData.orr.toFixed(1)}%`);
            }
            
            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2 + 5)
                .attr("text-anchor", "middle")
                .style("font-size", "13px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            const legendData = chartData.keys.map(key => {
                if (chartData.values[key] > 0) { 
                    return {
                        label: `${key} (${chartData.values[key].toFixed(1)}%)`,
                        color: color(key)
                    };
                }
                return null;
            }).filter(item => item !== null); 

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }

        // Data for Glofitamab + Chemo-Free Regimens in TP53-mutated R/R DLBCL (N=15 evaluable)
        // ORR: 66.7%, CRR: 40.0%
        // PRR = ORR - CRR = 66.7 - 40.0 = 26.7%
        // Other (SD/PD/NR) = 100 - ORR = 100 - 66.7 = 33.3%
        const glofitamabTp53ResponseData = {
            keys: ["CR", "PR", "Other (SD/PD/NR)"],
            values: { 
                CR: 40.0, 
                PR: 26.7, 
                "Other (SD/PD/NR)": 33.3 
            }, 
            colors: ["var(--sobi-teal)", "var(--sobi-yellow)", "var(--sobi-medium-gray-text)"],
            orr: 66.7 
        };
        
        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => {
                    clearTimeout(timeout);
                    func(...args);
                };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawGlofitamabTp53Chart = debounce(() => drawStackedBarChart("#glofitamabTp53ResponseChart", "#glofitamabTp53ResponseLegend", glofitamabTp53ResponseData, "Response at End of 6th Cycle (N=15)"), 250);
        
        window.addEventListener('resize', () => {
            debouncedDrawGlofitamabTp53Chart();
        });
        
        document.addEventListener('DOMContentLoaded', () => {
            debouncedDrawGlofitamabTp53Chart();
        });
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(() => {
                debouncedDrawGlofitamabTp53Chart();
             }, 0); 
        }
    </script>
</body>
</html>
